Technical Analysis for CLVS - Clovis Oncology, Inc.

Grade Last Price % Change Price Change
F 5.66 1.98% 0.11
CLVS closed up 1.98 percent on Thursday, March 4, 2021, on 1.3 times normal volume. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CLVS trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 1.98%
Wide Bands Range Expansion 1.98%
Oversold Stochastic Weakness 1.98%
Fell Below 200 DMA Bearish -1.05%
New Downtrend Bearish -1.05%
Wide Bands Range Expansion -1.05%
Oversold Stochastic Weakness -1.05%
Older End-of-Day Signals for CLVS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 7 hours ago
200 DMA Resistance about 8 hours ago
60 Minute Opening Range Breakout about 9 hours ago
Rose Above Previous Day's High about 9 hours ago
Up 5% about 9 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Clovis Oncology, Inc. Description

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has two clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, which is Phase I/II study is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is the subject of a development program for the treatment of non-small cell lung cancer in patients with activating EGFR mutations, as well as the primary resistance mutation, T790M; and rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase that is being explored in Phase I/II clinical trials for ovarian and breast cancer patients with BRCA mutations and other DNA repair deficiencies. The company's drug discovery program includes its mutant cKit inhibitor discovery program targeting the resistance mutations that occur in the majority of gastrointestinal stromal tumor patients and result in disease progression. It has license agreements with Avila Therapeutics, Inc. and Pfizer Inc.; a drug discovery collaboration agreement with Array BioPharma Inc.; and collaborations with Roche Molecular Systems and Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Disease Chemical Compounds Organic Compounds Gastrointestinal Drug Discovery Breast Cancer Treatment Of Breast Cancer Small Cell Lung Cancer Non Small Cell Lung Cancer Adp Epidermal Growth Factor Receptor Lung Cancer Treatment Of Non Small Cell Lung Cancer Gastrointestinal Stromal Tumor Lactams Indoles Foundation Medicine Heterocyclic Compounds

Is CLVS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 11.1
52 Week Low 3.62
Average Volume 8,712,111
200-Day Moving Average 6.04
50-Day Moving Average 6.57
20-Day Moving Average 7.28
10-Day Moving Average 6.06
Average True Range 0.68
ADX 22.91
+DI 24.22
-DI 24.70
Chandelier Exit (Long, 3 ATRs ) 9.05
Chandelier Exit (Short, 3 ATRs ) 7.55
Upper Bollinger Band 10.35
Lower Bollinger Band 4.21
Percent B (%b) 0.24
BandWidth 84.26
MACD Line -0.42
MACD Signal Line -0.16
MACD Histogram -0.2582
Fundamentals Value
Market Cap 585.43 Million
Num Shares 103 Million
EPS -7.50
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 2.19
Price-to-Book 0.00
PEG Ratio 0.13
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.48
Resistance 3 (R3) 6.52 6.29 6.34
Resistance 2 (R2) 6.29 6.08 6.27 6.30
Resistance 1 (R1) 5.98 5.95 6.13 5.93 6.25
Pivot Point 5.75 5.75 5.83 5.72 5.75
Support 1 (S1) 5.43 5.54 5.59 5.39 5.07
Support 2 (S2) 5.20 5.41 5.18 5.02
Support 3 (S3) 4.89 5.20 4.98
Support 4 (S4) 4.84